Analysis

Lisata Therapeutics, Inc. (LSTA) Stock Analysis

Lisata Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to LSTA.

websiteLSTA/analysis/LSTA

Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to LSTA.

Stock profile

Ticker

LSTA

Asset type

Stock

Market cap

$32.4M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Lisata Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • LSTA primary listing
  • A3DWGC
  • 8NE
  • 0HS8

Latest Lisata Therapeutics, Inc. news

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingen...

Kuva Intends to Commence Tender Offer for Lisata Therapeutics by May 29, 2026

Kuva reaffirms commitment to previously announced acquisition terms HOUSTON, TX, UNITED STATES, May 4, 2026 /⁨EINPresswire.com⁩/ -- On May 3, 2026, Kuva Labs,

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share Board of...

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Lisata regains full development rights to certepetide in the Greater China RegionBASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ...

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an appr...

Research sections

Valuation

Review valuation context for Lisata Therapeutics, Inc..

Future growth

Review future growth context for Lisata Therapeutics, Inc..

Past performance

Review past performance context for Lisata Therapeutics, Inc..

Financial health

Review financial health context for Lisata Therapeutics, Inc..

Dividend

Review dividend context for Lisata Therapeutics, Inc..

Management

Review management context for Lisata Therapeutics, Inc..

Ownership

Review ownership context for Lisata Therapeutics, Inc..

Other information

Review other information context for Lisata Therapeutics, Inc..

Community

Review community context for Lisata Therapeutics, Inc..